| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1MEF | Registration of up to an additional 20% of securities for any offering registered on an S-1 |
Registration Statements
|
||
| S-3 | Simplified registration form |
Registration Statements
|
||
| S-3 | Simplified registration form |
Registration Statements
|
||
| S-3 | Simplified registration form |
Registration Statements
|
||
| S-3 | Simplified registration form |
Registration Statements
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
